drugset
Drugs / TORL-1-23
last change Aug 2026 re-read 9 days ago

TORL-1-23

Other / unclassified

Developed for
primary peritoneal carcinoma · endometrial cancer · fallopian tube cancer · fallopian tube carcinoma · non-small cell lung carcinoma · ovarian cancer · ovarian endometrial cancer · uterine adnexa cancer
Investigated by
TORL Biotherapeutics, LLC · European Network of Gynaecological Oncological Trial Groups (ENGOT) · Translational Research in Oncology

Trials 3

today NCT07322094 · Ph 1/2 NCT06690775 · Ph 2 NCT05103683 · Ph 1
2022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05103683 Nov 2021 → Aug 2026 overdue endometrial cancer, non-small cell lung carcinoma, ovarian cancer TORL Biotherapeutics, LLC Recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07322094 Dec 2025 → Dec 2027 expected fallopian tube carcinoma, primary peritoneal carcinoma, uterine adnexa cancer TORL Biotherapeutics, LLC Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06690775 Nov 2024 → Oct 2027 expected fallopian tube cancer, ovarian endometrial cancer, primary peritoneal carcinoma TORL Biotherapeutics, LLC Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as TORL-1-23 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05103683 ↗
2

NCT06690775 ↗

NCT07322094 ↗
Modality Other / unclassified “antibody drug conjugate (ADC)” NCT05103683 ↗
Route Intravenous “2.4mg/kg intravenous infusion” NCT06690775 ↗